Department of Gastroenterology, Aichi Medical University School of Medicine, 1-1 Yazakokarimata, Nagakute, Aichi 480-1195, Japan.
BMC Gastroenterol. 2013 May 8;13:81. doi: 10.1186/1471-230X-13-81.
Recently, the relationship between gut microbiota and obesity has been highlighted. The present randomized, double-blind, placebo-controlled study aimed to evaluate the efficacy of transglucosidase (TGD) in modulating blood glucose levels and body weight gain in patients with type 2 diabetes mellitus (T2DM) and to clarify the underlying mechanism by analyzing the gut microbiota of T2DM patients.
This study included 60 patients who received placebo or TGD orally (300 or 900 mg/day) for 12 weeks, and blood and fecal samples were collected before and after 12 weeks. Comparisons of fecal bacterial communities were performed before and after the TGD treatment and were performed between T2DM patients and 10 healthy individuals, using the terminal-restriction fragment length polymorphism analysis.
The Clostridium cluster IV and subcluster XIVa components were significantly decreased, whereas the Lactobacillales and Bifidobacterium populations significantly increased in the T2DM patients compared with the healthy individuals. By dendrogram analysis, most of the healthy individuals (6/10) and T2DM patients (45/60) were classified into cluster I, indicating no significant difference in fecal bacterial communities between the healthy individuals and the T2DM patients. In the placebo and TGD groups, the bacterial communities were generally similar before and after the treatment. However, after 12 weeks of TGD therapy, the Bacteroidetes-to-Firmicutes ratio in the TGD groups significantly increased and was significantly higher compared with that in the placebo group, indicating that TGD improved the growth of the fecal bacterial communities in the T2DM patients.
Therefore, TGD treatment decreased blood glucose levels and prevented body weight gain in the T2DM patients by inducing the production of oligosaccharides in the alimentary tract and modulating gut microbiota composition.
UMIN-CTR UMIN000010318.
最近，肠道微生物群与肥胖之间的关系受到了关注。本随机、双盲、安慰剂对照研究旨在评估转葡糖基酶（TGD）在调节 2 型糖尿病（T2DM）患者的血糖水平和体重增加方面的疗效，并通过分析 T2DM 患者的肠道微生物群来阐明其潜在机制。
本研究纳入了 60 例患者，他们分别口服安慰剂或 TGD（300 或 900mg/天），疗程为 12 周，分别在治疗前和治疗 12 周后采集血样和粪便样本。采用末端限制性片段长度多态性分析（terminal-restriction fragment length polymorphism analysis）比较 TGD 治疗前后粪便细菌群落的变化，并将 T2DM 患者与 10 例健康个体进行比较。
与健康个体相比，T2DM 患者中梭菌属 IV 簇和亚簇 XIVa 成分显著减少，而乳杆菌目和双歧杆菌属的丰度显著增加。通过聚类分析，大多数健康个体（10 例中的 6 例）和 T2DM 患者（60 例中的 45 例）被归类为 I 类，表明健康个体和 T2DM 患者的粪便细菌群落无显著差异。在安慰剂组和 TGD 组中，治疗前后的细菌群落总体相似。然而，在 TGD 治疗 12 周后，TGD 组的拟杆菌门/厚壁菌门比值显著增加，且明显高于安慰剂组，表明 TGD 改善了 T2DM 患者粪便细菌群落的生长。
因此，TGD 治疗通过在消化道中产生低聚糖并调节肠道微生物群组成，降低了 T2DM 患者的血糖水平并防止体重增加。
UMIN-CTR UMIN000010318。
